Clinical Edge Journal Scan

Alcohol as a trigger for migraine: What is the link?


 

Key clinical point: Alcohol intake slightly reduced the likelihood of migraine attacks 48 hours after consumption in an English-speaking cohort of patients with episodic migraine who identified themselves as mostly low-dose alcohol consumers.

Major finding: The probability of migraine attack 48 hours after consuming alcohol was 25% lower than that after no alcohol consumption (adjusted odds ratio 0.75; 95% CI 0.68-0.82); however, alcohol consumption had no significant effect on migraine probability 24 hours after consumption.

Study details: This observational prospective cohort study included 487 patients with episodic migraine who reported 5913 migraine attacks and were alcohol consumers.

Disclosures: The study was partially funded by Curelator, Inc. M Vives-Mestres and A Casanova declared receiving consulting fees and holding stock options in Curelator, Inc. N Rosen reported ties with a headache society, journals, and various other sources.

Source: Vives-Mestres M et al. Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English-speaking countries. Headache. 2022;62:1329-1338. (Nov 27). Doi: 10.1111/head.14428

Recommended Reading

Elevated peripheral inflammatory markers may help support migraine diagnosis
Migraine ICYMI
Do autonomic symptoms influence headache frequency and treatment response in migraine?
Migraine ICYMI
Calcified neurocysticercosis influences disease severity and treatment response in migraine
Migraine ICYMI
Increased risk for migraine among individuals with childhood cancer
Migraine ICYMI
Adenosine induces headache and short-lasting vasodilation but not migraine attacks
Migraine ICYMI
Galcanezumab reduces migraine severity and symptoms in episodic migraine
Migraine ICYMI
Migraine in children and teens: managing the pain
Migraine ICYMI
Commentary: Risk factors and treatment for pediatric migraine, December 2022
Migraine ICYMI
High drug costs exclude most neurology patients from cutting-edge treatment
Migraine ICYMI
Evidence supporting atogepant as a promising treatment for migraine prevention
Migraine ICYMI